444 results on '"Rech, Jürgen"'
Search Results
2. Treatment patterns of individualized real-life tapering approaches based on shared decision-making in rheumatoid arthritis
3. Clinical presentation and genetic variants in patients with autoinflammatory diseases: results from the German GARROD registry
4. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial
5. Diagnosis and treatment of adult-onset Still’s disease: a concise summary of the German society of rheumatology S2 guideline
6. DGRh-S2e-Leitlinie: Diagnostik und Therapie des adulten Still-Syndroms (AOSD)
7. Leitlinienreport zur DGRh-S2e-Leitlinie Diagnostik und Therapie des adulten Still-Syndroms (AOSD)
8. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial
9. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial
10. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial
11. Erratum to: Diagnosis and treatment of adult-onset Still’s disease: a concise summary of the German society of rheumatology S2 guideline
12. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial
13. Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial
14. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study
15. Patient Experiences and Challenges in the Management of Autoinflammatory Diseases—Data from the International FMF & AID Global Association Survey
16. Anti-Interleukin-1 Therapy Does Not Affect the Response to SARS-CoV-2 Vaccination and Infection in Patients with Systemic Autoinflammatory Diseases
17. Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis
18. The Joint Vasculitis Registry in German-speaking countries (GeVas) – a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis
19. Autoinflammation leading to autoimmunity in adult-onset Still’s disease: more than simple coincidence?
20. Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials
21. Clinical presentation and genetic variants in patients with autoinflammatory diseases: results from the German GARROD registry
22. A comparative analysis of articular bone in large cohort of patients with chronic inflammatory diseases of the joints, the gut and the skin
23. Towards a pro-resolving concept in systemic lupus erythematosus
24. Secukinumab leads to shifts from stage-based towards response-based disease clusters—comparative data from very early and established psoriatic arthritis
25. Quantification of hand muscle volume and composition in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis
26. A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations
27. IgA subclasses have different effector functions associated with distinct glycosylation profiles
28. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs
29. Organisation einer Studienambulanz und prüfstellenspezifische Formalitäten
30. Physical Function of RA patients Tapering Treatment—A Post Hoc Analysis of the Randomized Controlled RETRO Trial
31. Presence of HLA-B27 is associated with changes of serum levels of mediators of the Wnt and hedgehog pathway
32. VEXAS syndrome mimicking lupus-like disease
33. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial
34. Diagnosis and treatment of adult-onset Still’s disease: a concise summary of the German society of rheumatology S2 guideline
35. DGRh-S2e-Leitlinie
36. Brain oedema due to disseminated intravascular coagulation in a patient with adult-onset Still’s disease–associated hemophagocytic lymphohistiocytosis—a case report
37. Cortical bone loss is an early feature of nonradiographic axial spondyloarthritis
38. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study
39. Erste Analysen zu einer durch Patienten mit autoinflammatorischen Erkrankungen organisierten internationalen Befragung – FMF&AID
40. Die 'ARIAA-Studie' – Abatacept verzögert den Übergang in eine RA bei at-risk-Patienten – klinische Ergebnisse zu Monat 18 der internationalen, randomisiert, placebo kontrollierten Studie
41. Langzeitwirksamkeit und Sicherheit von Canakinumab bei Patienten mit HIDS (Hyper-IgD-Syndrom) – Interimsanalyse des RELIANCE-Registers
42. VERhO – patientenindividuelles Tapering von DMARDs bei Patienten mit rheumatoider Arthritis in der Versorgungspraxis
43. Impfsicherheit unter Canakinumab bei Patienten mit autoinflammatorischen periodischen Syndromen – Interimsanalyse des RELIANCE-Registers
44. Add-on or withdrawal of methotrexate do not impact efficacy of IL12/23 inhibition in active PsA: Data from the multicenter investigator-initiated randomized placebo-controlled MUST trial
45. Langzeitsicherheit und Wirksamkeit von Canakinumab bei Cryopyrin-assoziierten periodischen Syndromen (CAPS) – 36-Monats-Daten aus dem RELIANCE-Register
46. Langzeitwirksamkeit und Sicherheit von Canakinumab bei Patienten mit familiärem Mittelmeerfieber (FMF) – Zwischenanalyse des RELIANCE-Registers
47. Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting
48. Towards preventive treatment of rheumatoid arthritis
49. Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs
50. Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.